Improvement of atopic dermatitis-like skin lesions by IL-4 inhibition of P14 protein isolated from Lactobacillus casei in NC/Nga mice

Kim, Min‐Soo; Kim, Jin-Eung; Yoon, Yeo-Sang; Kim, Tai Hoon; Seo, Jae-Gu; Chung, Myung Jun; Yum, Do-Young

doi:10.1007/s00253-015-6455-y

Cited by 7 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atopic dermatitis is a major allergic disease that results in increased IgE levels and clinically manifests itself as pruritic skin lesions, dermal hyperkeratosis, and hyperplasia ( Abramovits, 2005 ; Silverberg, 2016 ). Recent studies have shown that certain probiotics can play a role in the treatment and prevention of AD ( Kim et al, 2012 , 2015 ). Duolac ATP possesses anti-inflammatory properties in a DNCB-induced AD mouse model ( Kim et al, 2016 ).…”

Section: Discussionmentioning

confidence: 99%

A Probiotic Mixture Regulates T Cell Balance and Reduces Atopic Dermatitis Symptoms in Mice

et al. 2018

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disorder with a complex etiology involving the immune response. Recent studies have demonstrated the role of certain probiotics in the treatment and prevention of AD. However, the mechanism by which these probiotics regulate the immune system remains unclear. In this study, we examined the immunomodulatory capacity of Duolac ATP, a mixed formulation of probiotics, both in vitro and in vivo. Results showed that the expression of programmed death-ligand 1(PD-L1) was significantly upregulated on bone marrow-derived dendritic cells (BMDCs) treated with Duolac ATP. Furthermore, the anti-inflammatory cytokines IL-10 and TGF-beta were both upregulated when BMDCs were treated with Duolac ATP. The percentage of proliferated regulatory T cells (Tregs) was enhanced when CD4+ T cells were co-cultured with Duolac ATP-treated BMDCs on plates coated with anti-CD3/CD28 antibodies. Intriguingly, IL-10 secretion from CD4+ T cells was also observed. The AD symptoms, histologic scores, and serum IgE levels in AD mice were significantly decreased after oral treatment with Duolac ATP. Moreover, the Th1-mediated response in AD-induced mice treated with oral Duolac ATP showed upregulation of IL-2 and IFN-gamma as well as of downstream signaling molecules T-bet, STAT-1, and STAT-4. Conversely, Duolac ATP suppressed Th2 and Th17 responses in AD-like mice, as evidenced by the downregulation of GATA-3, C-maf, IL-4, IL-5, and IL-17. Additionally, Duolac ATP increased the number of Tregs found at Peyer’s patches (PP) in treated AD mice. These results suggest that Duolac ATP modulates DCs to initiate both Th1 and Treg responses in AD mice. Thus, Duolac ATP represents a potential preventative agent against AD and could serve as an effective immunomodulator in AD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A Probiotic Mixture Regulates T Cell Balance and Reduces Atopic Dermatitis Symptoms in Mice

et al. 2018

View full text Add to dashboard Cite

show abstract

“…During the Japanese cedar pollen season, NC/Nga mice orally administered L. casei Japan Collection of Microorganisms (JCM) 1134T combined with dextran experienced a possible effect on the prevention and treatment of allergic reactions ( Ogawa et al., 2006 ). Furthermore, researchers screened an active ingredient, protein P14, from the L. casei extract, which specifically lowered IgE and IL-4 levels in AD-like NC/Nga mice, suggesting potential therapeutic effects in AD ( Kim et al., 2015b ). Similarly, the administration of L. casei DN–114001 to the diet of children with AD was beneficial to the increase in the count of intestinal flora and its maintenance for five months after the cessation of probiotics ( Klewicka et al., 2011 ).…”

Section: Monostrain Lactobacillus In the Treatment...mentioning

confidence: 99%

Lactobacillus for the treatment and prevention of atopic dermatitis: Clinical and experimental evidence

Xie

Chen

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disease, accompanied by itching and swelling. The main pathological mechanism of AD is related to the imbalance between Type 2 helper cells (Th2 cells) and Type 1 helper cells (Th1 cells). Currently, no safe and effective means to treat and prevent AD are available; moreover, some treatments have side effects. Probiotics, such as some strains of Lactobacillus, can address these concerns via various pathways: i) facilitating high patient compliance; ii) regulating Th1/Th2 balance, increasing IL-10 secretion, and reducing inflammatory cytokines; iii) accelerating the maturation of the immune system, maintaining intestinal homeostasis, and improving gut microbiota; and iv) improving the symptoms of AD. This review describes the treatment and prevention of AD using 13 species of Lactobacillus. AD is commonly observed in children. Therefore, the review includes a higher proportion of studies on AD in children and fewer in adolescents and adults. However, there are also some strains that do not improve the symptoms of AD and even worsen allergies in children. In addition, a subset of the genus Lactobacillus that can prevent and relieve AD has been identified in vitro. Therefore, future studies should include more in vivo studies and randomized controlled clinical trials. Given the advantages and disadvantages mentioned above, further research in this area is urgently required.

show abstract

“…Similarly, an AD-like in vivo NC/Nga mice model demonstrated that the protein P14, isolated from Lactobacillus casei, can be used as an active immunomodulatory agent for treating patients with AD [74].…”

Section: Microorganism-derived Substancesmentioning

confidence: 99%

Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?

et al. 2020

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a pathological skin condition with complex aetiological mechanisms that are difficult to fully understand. Scientific evidence suggests that of all the causes, the impairment of the skin barrier and cutaneous dysbiosis together with immunological dysfunction can be considered as the two main factors involved in this pathological skin condition. The loss of the skin barrier function is often linked to dysbiosis and immunological dysfunction, with an imbalance in the ratio between the pathogen Staphylococcus aureus and/or other microorganisms residing in the skin. The bibliographic research was conducted on PubMed, using the following keywords: ‘atopic dermatitis’, ‘bacterial therapy’, ‘drug delivery system’ and ‘alternative therapy’. The main studies concerning microbial therapy, such as the use of bacteria and/or part thereof with microbiota transplantation, and drug delivery systems to recover skin barrier function have been summarized. The studies examined show great potential in the development of effective therapeutic strategies for AD and AD-like symptoms. Despite this promise, however, future investigative efforts should focus both on the replication of some of these studies on a larger scale, with clinical and demographic characteristics that reflect the general AD population, and on the process of standardisation, in order to produce reliable data.

show abstract

Improvement of atopic dermatitis-like skin lesions by IL-4 inhibition of P14 protein isolated from Lactobacillus casei in NC/Nga mice

Cited by 7 publications

References 40 publications

A Probiotic Mixture Regulates T Cell Balance and Reduces Atopic Dermatitis Symptoms in Mice

A Probiotic Mixture Regulates T Cell Balance and Reduces Atopic Dermatitis Symptoms in Mice

Lactobacillus for the treatment and prevention of atopic dermatitis: Clinical and experimental evidence

Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?

Contact Info

Product

Resources

About